menu
    • menu
    [{"orgOrder":0,"company":"Axonis Therapeutics","sponsor":"Kerry Murphy","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"KCC2","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"Axonis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Axonis Therapeutics \/ Kerry Murphy","highestDevelopmentStatusID":"2","companyTruncated":"Axonis Therapeutics \/ Kerry Murphy"},{"orgOrder":0,"company":"Axonis Therapeutics","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"AXN-027","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Axonis Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"","sponsorNew":"Axonis Therapeutics \/ Cormorant Asset Management","highestDevelopmentStatusID":"6","companyTruncated":"Axonis Therapeutics \/ Cormorant Asset Management"}]

    Find Clinical Drug Pipeline Developments & Deals by Axonis Therapeutics

    Menu

    Axonis Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Axonis Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Axonis Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AXN-027

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Cormorant Asset Management

                            Deal Size : $115.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Axonis Therapeutics Announces $115 Million Series A Financing

                            Details : The proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, which is being evaluated for the treatment of refractory epilepsy, chronic pain.

                            Product Name : AXN-027

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 30, 2024

                            Lead Product(s) : AXN-027

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Cormorant Asset Management

                            Deal Size : $115.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Axonis Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Axonis Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KCC2

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Discovery

                            Sponsor : Kerry Murphy

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy

                            Details : The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 28, 2020

                            Lead Product(s) : KCC2

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Discovery

                            Sponsor : Kerry Murphy

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth